Clinical experience on EGFR tyrosine kinase inhibitor in non-small cell lung cancer, compassionate programme in Czech Republic

被引：0
|
作者：
Pesek, M.
Skrickova, J.
Kolek, V.
Zatloukal, P.
Petruzelka, L.
Svobodnik, A.
机构：
[1] Fac Med, Dept TB & Pulm Dis, Plzen, Czech Republic
[2] Fac Med, Dept TB & Pulm Dis, Brno, Czech Republic
[3] Fac Med, Dept TB & Pulm Dis, Olomouc, Czech Republic
[4] Fac Med, Dept Pneumol & Thorac Surg, Prague 8, Czech Republic
[5] Fac Med, Dept Oncol Dis, Prague 2, Czech Republic
[6] Masaryk Univ, Ctr Biostat & Anal, Brno, Czech Republic
来源：
LUNG CANCER | 2006年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [21] Characterization of skin pathology in non-small cell lung cancer patients treated with the EGFR tyrosine kinase inhibitor erlotinib
    Krueger, James G.
    McCarthy, Sean P.
    Conlan, Maureen G.
    Iwata, Kenneth K.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB33 - AB33
  • [22] Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors
    Singh, Mahaveer
    Jadhav, Hemant R.
    DRUG DISCOVERY TODAY, 2018, 23 (03) : 745 - 753
  • [23] Tyrosine Kinase Inhibitor Gold Nanoconjugates for the Treatment of Non-Small Cell Lung Cancer
    Cryer, Alexander M.
    Chan, Cheuk
    Eftychidou, Anastasia
    Maksoudian, Christy
    Mahesh, Mohan
    Tetley, Teresa D.
    Spivey, Alan C.
    Thorley, Andrew J.
    ACS APPLIED MATERIALS & INTERFACES, 2019, 11 (18) : 16336 - 16346
  • [24] The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines
    Shen, Lan
    Li, Ziming
    Shen, Shengping
    Niu, Xiaomin
    Yu, Yongfeng
    Li, Zonghai
    Liao, Meilin
    Chen, Zhiwei
    Lu, Shun
    LUNG CANCER, 2012, 78 (03) : 193 - 200
  • [25] THE SYNTHETIC EFFECT OF AROMATASE INHIBITOR ANASTROZOLE IN COMBINATION WITH EGFR TYROSINE KINASE INHIBITOR GEFITINIB IN NON-SMALL CELL LUNG CANCER CELL LINES
    Shen, Lan
    Lu, Shun
    Zhang, Fei Y.
    Li, Ziming
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S724 - S725
  • [26] Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
    Krawczyk, Pawel
    Mlak, Radoslaw
    Powrozek, Tomasz
    Nicos, Marcin
    Kowalski, Dariusz M.
    Wojas-Krawczyk, Kamila
    Milanowski, Janusz
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2012, 16 (05): : 401 - 406
  • [27] EGFR tyrosine kinase inhibitors in non-small cell lung cancer: Report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients
    Reck, M
    Gatzemeier, U
    ONKOLOGIE, 2005, 28 (12): : 623 - 627
  • [28] Modulation of microRNA expression in EGFR-tyrosine kinase inhibitor-resistant non-small cell lung cancer cell lines
    Haque, Inamul
    Motes, Hannah
    Sharma, Mukut
    Reyes, Emma Borrego-Diaz
    Godwin, Andrew K.
    Huang, Chao H.
    CANCER RESEARCH, 2018, 78 (13)
  • [29] A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
    Gawli, Chandrakant S.
    Patil, Chandragouda R.
    Patel, Harun M.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2025, 123
  • [30] REVERSAL OF RESISTANCE TO EGFR TYROSINE KINASE INHIBITOR BY EGFR T790M SPECIFIC SIRNA IN NON-SMALL CELL LUNG CANCER
    Lee, Choon-Taek
    Park, Mi-Young
    Eo, Eun Young
    Park, Jong Sun
    Cho, Young Jae
    Yoon, Ho-Il
    Lee, Jae Ho
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S458 - S458
12345